Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

54.27
+3.717.34%
Post-market: 55.421.15+2.12%19:57 EDT
Volume:5.56M
Turnover:305.32M
Market Cap:8.31B
PE:19.60
High:56.87
Open:51.10
Low:49.97
Close:50.56
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:3.94
T/O Rate:3.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.75
PE(LYR):19.59

Loading ...

TG Therapeutics Credit Deal And Valuation Gap Catch Investor Attention

Simply Wall St.
·
Mar 22

TG Therapeutics Files Procedural 8-K on Financial Obligation

TIPRANKS
·
Mar 21

TG Therapeutics enters USD 750 billion term loan amendment with Blue Owl Capital Corporation-led lenders

Reuters
·
Mar 21

BRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million

Reuters
·
Mar 19

TG Therapeutics Inc - Enters Five-Year $750 Mln Credit Facility With Blue Owl Capital

THOMSON REUTERS
·
Mar 19

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital From Blue Owl and Expands Share Repurchase Program to $300 Million

THOMSON REUTERS
·
Mar 19

TG Therapeutics Inc - Increases Share Repurchase Program to $300 Mln

THOMSON REUTERS
·
Mar 19

TG Therapeutics announces publication of data from studies on Briumvi

TIPRANKS
·
Mar 09

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

GlobeNewswire
·
Mar 09

**TG Therapeutics to present BRIUMVI data at AAN 2026 annual meeting**TG Therapeutics Inc. will present two poster sessions on BRIUMVI (ublituximab-xiiy) data in relapsing forms of multiple sclerosis at the American Academy of Neurology 2026 annual meeting in Chicago

Reuters
·
Mar 06

TG Therapeutics Earnings Call Highlights BRIUMVI Surge

TIPRANKS
·
Mar 04

Precision BioSciences Receives $7.5 Million Milestone Payment From TG Therapeutics for Azer-cel MS Trial Progress

Reuters
·
Mar 02

TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth

TIPRANKS
·
Mar 01

Stock Track | TG Therapeutics Soars 5.12% Intraday on Strong Earnings and Raised 2026 Revenue Guidance

Stock Track
·
Feb 27

TG Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 26

TG Therapeutics Q4 revenue rises on BRIUMVI sales, but profit dips

Reuters
·
Feb 26

Earnings Flash (TGTX) TG Therapeutics Posts Q4 EPS $0.14, vs. FactSet Est of $0.35

MT Newswires Live
·
Feb 26

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $897.64M

TIPRANKS
·
Feb 26

Stock Track | TG Therapeutics Plunges 6.44% in Pre-Market After Q4 Earnings Miss

Stock Track
·
Feb 26

TG Therapeutics posts FY 2025 net income of USD 447.2 million (92.0% growth)

Reuters
·
Feb 26